Mergers & Acquisitions Mergers & Acquisitions

Danaher-GE BioPharma approved in South Korea, with bioprocessing divestment conditions

By Choi Hyung-jo
  • 03 Feb 2020 22:13
  • 03 Feb 2020 22:38

Danaher's proposed acquisition of GE BioPharma has been cleared in South Korea, conditional on a divestment package.

The Korea Fair Trade Commission has granted approval to Danaher's $21.4 billion acquisition of the biopharma unit of GE Healthcare's Life Sciences, an affiliate of General Electric, on condition that eight of the companies' bioprocessing businesses

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

TAKE A FREE TRIAL

Latest News